The necessity of treatment for small gastric subepithelial tumors (1–2 cm) originating from muscularis propria: an analysis of 972 tumors

Jinlong Hu, Xinzhu Sun, Nan Ge, Sheng Wang, Jintao Guo, Xiang Liu, Guoxin Wang and Siyu Sun*

Abstract

Background and objectives: Up till now, there are still controversies about the specific indication of endoscopic resection for small gastric subepithelial tumors (gSETs) originating from muscularis propria. We aimed to investigate the safety of endoscopic resection and postoperative pathology analysis.

Method: The patients with primary small gSETs originating from muscularis propria, treated by endoscopic resection in the endoscopic center of Shengjing Hospital between January, 2011 and September, 2019 were enrolled. The complete resection rate, adverse events and clinicopathological features were recorded.

Result: A total of 936 patients with 972 gastric SETs ≤ 2 cm originating from muscularis propria were included in our study. All the lesions were successfully treated by endoscopic resection. Nearly half of lesions were proved to be gastrointestinal stromal tumor (GIST) [n = 411 (42.3%)] according to postoperative pathology. All the objects were further subdivided into 2 groups, ≤ 1 cm, > 1 and ≤ 2 cm gSETs. The risk of gastric GIST of intermediate/high risk in the group (> 1 and ≤ 2 cm gSETs) is 8.41 times as that of gastric GIST in the group (the size of gastric ≤ 1 cm gSETs) (P < 0.05).

Conclusion: Endoscopic resection is a safe and effective treatment for small gSETs. gSETs (1–2 cm) is more risky than gSETs (< 1 cm) and should be resected. This should be evaluated by further studies.

Keywords: Gastric subepithelial tumor, Gastrointestinal stromal tumor, Endoscopic ultrasound

Introduction

As reported by earlier literature, the incidence of gastric subepithelial tumors (gSETs) for routine gastroscopy examination was about 0.36–1.94% [1–3]. Gastrointestinal stromal tumors (GISTs), usually originating from the muscularis propria [4], are the most common type of gSETs [5] and considered potentially malignant. According to the latest guidelines published by European Sarcoma Network Working Group [6] and National Comprehensive Cancer Network [7, 8], surveillance and follow-up, other than positive excision, are recommended for gSETs ≤ 2 cm without high-risk endoscopic ultrasonography (EUS) features or related clinical symptoms, since they are of very low risk of malignancy and metastasis. However, a portion of scholars hold that small gSETs, especially GISTs of intermediate or high risk, should be resected as soon as detected in order to make a confirm diagnosis and to avoid further malignancy [9]. Moreover, endoscopic procedures are extremely suitable for these gSETs [10].

Several studies have proved the efficacy and safety of endoscopic resection for small gSETs [11–13]. However,
few studies have concentrated on necessity for the resection of small gSETs. The current criterion for small gSETs resection may not find all the high risky lesions. In the present study, we used a larger sample size to analyze safety and necessity of endoscopic management and clinicopathological data of small gSETs $\leq 2$ cm originating from the muscularis propria.

**Patients and methods**

**Patients**

In the present study, we included the demographic and clinicopathological results of 936 consecutive patients with 972 primary small gastric SETs originating from muscularis propria, treated by endoscopic resection in the endoscopic center of Shengjing Hospital of China Medical University between January, 2011 and September, 2019. If the lesion involved more layers, it was excluded. All the patients in the present study asked to remove gastric lesion. All patients were evaluated by computed tomography and endoscopic ultrasound (EUS) (The maximum diameter $< 2.0$ cm). The EUS characteristics of the lesion, endoscopic treatment, adverse events and postoperative pathology were analyzed. Furthermore, we analyzed whether the size of GIST larger than 1 cm was responsible for the postoperative pathology to be intermediate or high-risk according to the modified NIH risk stratification via Chi-Squared Test. All included patients were provided with written informed consent to undergo endoscopic resection and this study was supported by the institutional review board of Shengjing hospital.

**Endoscopic treatment**

All the procedures were performed under general anesthesia. The details of band ligation and resection, endoscopic submucosal dissection, endoscopic full-thickness resection and submucosal tunneling endoscopic resection were described in various studies [14–16]. Postoperative histology evaluation and immunohistochemistry was used to identify tumor type.

**Results**

936 patients with 972 gastric SETs $\leq 2$ cm originating from muscularis propria were included in our study (Table 1). Among the 936 patients, 213 were male (22.8%), 723 were female (77.2%). The mean age was 53.6 $\pm$ 10.2 years (range 16–78 years). The median value for maximal tumor size was 9.6 $\pm$ 3.9 mm (range 3–20 mm). All the lesions were successfully treated by endoscopic resection. Three patients experienced postoperative bleeding, which were successfully managed by endoscopic hemostasis. Two patients experienced postoperative perforation. One patient was treated by conservative treatment and one patient received surgery. Pathological diagnosis were leiomyoma $[n = 485 (49.9\%)]$, GIST $[n = 411 (42.3\%)]$, schwannoma $[n = 20 (2.1\%)]$, ectopic pancreas $[n = 12 (1.2\%)]$ and other tumors or tissues $[n = 44 (4.5\%)]$. The details of patients with GIST were listed in Table 2. According to the modified NIH risk classification system, there were 376 cases (91.5%) of very low risk, 25 cases (6.1%) of low risk, 8 cases (1.9%) of intermediate risk and 2 cases (0.5%) of high risk. Only two patients with intermediate or high risk GIST had epigastric discomfort. Ultimately, we analyzed whether size $> 1$ cm was correlated with

| Table 1 | Clinical characteristics of the 936 patients with 972 gastric SETs $\leq 2$ cm |
|---------|------------------------------------------------------------------|
| Age [year; mean $\pm$ SD; (range)] | 53.6 $\pm$ 10.2 (16–78) |
| Gender [n (%)] | |
| Male | 213 (22.8%) |
| Female | 723 (77.2%) |
| Tumor diameter [mm; mean $\pm$ SD] | 9.6 $\pm$ 3.9 |
| Location [n (%)] | |
| Fundus | 558 (57.4%) |
| Corpus | 390 (40.1%) |
| Angle | 3 (0.3%) |
| Antrum | 21 (2.2%) |
| Pathological diagnosis [n (%)] | |
| Leiomyoma | 485 (49.9%) |
| GIST | 411 (42.3%) |
| Schwannoma | 20 (2.1%) |
| Ectopic pancreas | 12 (1.2%) |
| Vascular malformation/proliferation | 8 (0.8%) |
| Inflammatory tissue | 17 (1.7%) |
| Hamartoma | 5 (0.5%) |
| Glomus tumor | 4 (0.4%) |
| Neuroendocrine neoplasm | 3 (0.3%) |
| Calcified tissue | 3 (0.3%) |
| Collagenoma | 2 (0.2%) |
| Hemangioma | 1 (0.1%) |
| Fibroma | 1 (0.1%) |
| Endoscopic procedures [n (%)] | |
| BLR | 418 (43) |
| ESD | 344 (35.4) |
| EFTR | 201 (20.7) |
| STER | 9 (0.9) |
| Complete resection | 972 |
| Postoperative complications | |
| Perforation | 2 |
| Bleeding | 3 |

BLR: band ligation and resection, ESD: endoscopic submucosal dissection, EFTR: endoscopic full-thickness resection, STER: submucosal tunneling endoscopic resection.
the postoperative pathology to be intermediate or high-risk according to the modified NIH risk stratification via Chi-Squared Test. Therefore, tumors are more likely to be of relatively higher risk when the sizes are larger than 1 cm. The OR value was 8.41, that is, the risk of gastric GIST of intermediate/high risk in the group (the size of gastric subepithelial tumor ranging 1–2 cm) is 8.41 times as that of gastric GIST in the group (the size of gastric subepithelial tumor less than 1 cm) ($P < 0.05$) (Table 3).

Discussion

With the development of endoscopic techniques and improvement of health awareness, the detection rate of gSETs has increased in recent years [17]. On the basis of the biological behavior and cytological characteristics, gSETs are classified into non-neoplastic and neoplastic lesions [5]. Non-neoplastic SETs usually manifest as benign lesions, such as inflammation, cysts, ectopic pancreas, etc. On the contrary, a portion of neoplastic gSETs are malignant or potentially malignant lesions, such as GISTs. Among all the neoplastic SETs of digestive tract, GISTs are considered as the most common tumor and potentially malignant neoplasms originating from the interstitial cells of Cajal [18]. GISTs account for 1/5 of sarcoma of gastrointestinal tract and represent 1–2% of all gastrointestinal malignancies [19] and more than a half of them are located in the stomach [20, 21].

Based on EUS guideline [22], EUS is the most effective method for differentiating between an intramural and extramural lesion and for evaluating the characteristics, such as layer of origin, size, margin and echogenicity, of subepithelial lesions. But it is difficult to make differential diagnosis of gastric tumor originating from muscularis propria by EUS, especially for small lesion. Based on the big lesions, some authors concluded that high-risk EUS features provided evidence for diagnosis of malignant or potentially malignant GISTs, including irregular border, cystic spaces, ulceration, echogenic foci, and heterogeneity [23, 24]. Moreover, contrast-enhanced EUS can be used for differentiation [25] and intra-tumoral vessels observed in GISTs using contrast-enhanced EUS was proved to be correlated with higher malignant potential by the study of Yasunobu [26]. However, studies also showed that ultrasonographic features of smaller lesions might not have been as sensitive as those of larger ones [27]. In our study, EUS could not predict the potential malignancy of GISTs. Besides, a number of EUS-related sampling strategies, such as EUS-guided fine needle aspiration (EUS-FNA) [28–30], EUS-guided core needle biopsy [31], as well as the latest “ligate unroof biopsy” technique [32], have emerged to assist differential

| Table 2 | Clinical features and endoscopic procedure of 411 GISTs of 403 patients |
|---------|---------------------------------------------------------------------|
| Age [year; mean ± SD; (range)] | 56.5 ± 8.6 (29–78) |
| Gender [n (%)] | |
| Male | 115 (28.5%) |
| Female | 288 (71.5%) |
| Tumor diameter [mm; mean ± SD] | 9.7 ± 4.1 |
| Location [n (%)] | |
| Fundus | 288 (69.8) |
| Corpus | 114 (18.7) |
| Antrum | 9 (2.2) |
| Pathological diagnosis [n (%)] | |
| Very-low risk | 376 (91.5) |
| Low risk | 25 (6.1) |
| Intermediate risk | 8 (1.9) |
| High risk | 2 (0.5) |
| Endoscopic procedures [n (%)] | |
| BLR | 159 (38.6) |
| ESD | 118 (28.7) |
| EFTR | 133 (32.4) |
| STER | 1 (0.1) |
| EUS features | |
| Hypoechoic lesion | 411 |
| Irregular border | 0 |
| Cystic spaces | 0 |
| Ulceration | 0 |
| Heterogeneity | 0 |

| Table 3 | Pathological characteristics according to tumor size |
|---------|---------------------------------------------|
| ≥ 1 and ≤ 2 cm | ≤ 1 cm | Total |
| GISTs of intermediate/high risk (n$_1$) | 8 | 2 | 10 |
| Gastric tumors other than GISTs of intermediate/high risk (n$_2$) | 310 | 652 | 962 |
| Total | 318 | 654 | 972 |
| OR | 8.41 |
| $\chi^2$ | $8.20 > \chi^2_{0.05,1} = 3.84, P < 0.05$ |
not be sufficient tissues obtained by biopsy for the assessment of mitotic or genetic mutation [36]. Due to heterogeneity of most tumors, pathologists cannot determine the level of mitoses of GISTs through samples gained by FNA or other biopsy strategies since the cellularity and the mitotic count of GISTs are inconsistent in different sites within the tumors.

Up till now, there are still controversies about the specific indication of endoscopic resection for small gastric gSETs originating from muscularis propria. According to the guidelines published by ESMO in 2014, the standard approach to the small, asymptomatic, upper gastrointestinal SETs ≤ 2 cm is EUS assessment and then annual follow-up, reserving excision for tumors which increase in size or for patients who turn symptomatic [6]. The NCCN guidelines (2010) also suggested that, for patients without high-risk EUS features (i.e. irregular border, cystic spaces, ulceration, echogenic foci, and heterogeneity), a follow-up with EUS was recommended every 6–12 months [7, 8]. In other words, surveillance and follow-up, other than positive excision, are recommended for SETs < 2 cm by the guidelines. However, differentiation between potentially malignant GISTs and other benign or non-neoplastic lesions is extremely difficult by image method, especially for small lesions. In addition, some studies found small GISTs (< 2 cm) may be intermediate or high risk. Yang et al. reported that there were 7 cases (2.5%) of intermediate risk and 10 cases (3.6%) of high risk in gastric GISTs (< 2 cm) in their study [17]. Pang et al. reported that 9 patients (3.9%) were in intermediate risk group and 2 patients (0.9%) were in high risk group, in which the tumor size in both cases was less than 2 cm [11]. Gao et al. found EUS-suspected GISTs larger than 9.5 mm may be associated with significant progression [27]. In a study from Italy, in which 170 GISTs measuring 2 cm or smaller were analyzed, mitotic activity dramatically increased once the tumor size exceeded 1 cm, compared with tumors smaller than 1 cm [37]. In our study, the lesions (between 1 and 2 cm) was more risky than lesions (< 1 cm). The OR value was 8.41. So the lesion (> 1 cm) had more potential to become malignant lesion and should be resected. Except GISTs, some other tumors originating from muscularis propria, such as gastric glomus tumor, are also potentially malignant.

So in our opinion, we should resect gastric submucosal tumor originating from muscularis propria, if the size is larger than 1 cm. In addition, the study found that 27.6% (16/58) patients experienced a severe psychological illness and seriously affected their quality of life [9]. Due to the possibility of potential malignancy or malignancy, many patients tolerated the psychological stress and preferred to receive endoscopic treatment, instead of a regular follow-up.

Endoscopic resection methods, such as endoscopic submucosal dissection, endoscopic submucosal excavation, endoscopic full-thickness resection [38] and band ligation and resection, are widely used in clinical practice to remove gSETs originating from muscularis propria, showing low incidence of complications and the same therapeutic effect as open surgery and laparoscopic surgery [11, 13, 39–41]. In our study, all the lesions were successfully removed by endoscopic method and postoperative bleeding and perforation were managed by endoscopic method or conservative treatment, expect for one postoperative perforation, which was managed by surgery in the early time. With the development of endoscopic equipments, postoperative perforation could be managed by endoscopic method and following conservative treatment [42].

In conclusion, endoscopic resection may be suitable for the management of patients with small gastric SETs (1–2 cm) in order to make confirm diagnosis, to accomplish curative treatment, and to avoid potential malignancy. As for gSETs (< 1 cm), endoscopic and/or radiological surveillance should be recommended. Further studies should be conducted to confirm it.

Abbreviations
gSETs: Gastric subepithelial tumors; GIST: Gastrointestinal stromal tumor; EUS-FNA: EUS-guided fine needle aspiration; EUS: Endoscopic ultrasonography.

Acknowledgements
None.

Author contributions
JLH and XZS: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; NG, SW, JTGXL, and GXW: study concept and design; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; SYS: study concept and design; analysis and interpretation of data; critical revision of the manuscript for important intellectual content administrative, technical, or material support; study supervision. All authors read and approved the final manuscript.

Funding
This study was supported by National Key Research and Development Project of China to Siyu Sun (Grant No. 2017YFC0109803) and 345 talent project of Jinlong Hu.

Availability of data and materials
The dataset supporting the conclusions of this article is available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
This was a retrospective study. It was approved by our institution's Institutional Review Board of Shengjing Hospital of China Medical University and written informed consent was obtained from all subjects. All methods were carried out in accordance with relevant guidelines and regulations.

Consent to publish
Not applicable.

Competing interests
The authors have no competing interests to declare.

Received: 7 September 2021 Accepted: 28 March 2022 Published online: 11 April 2022

References
1. Hedenbro JL, Ekelund M, Wetterberg P. Endoscopic diagnosis of submucosal gastric lesions. The results after routine endoscopy. Surg Endosc. 1991;5:20–3.
2. Lim YJ, Son HJ, Lee JS, et al. Clinical course of subepithelial lesions detected on upper gastrointestinal endoscopy. World J Gastroenterol. 2010;16:439–44.
3. Song JH, Kim SG, Chung SJ, et al. Risk of progression for incidental small subepithelial tumors in the upper gastrointestinal tract. Endoscopy. 2015;47:675–9.
4. Alkhathib AA, Faigel DO. Endoscopic ultrasonography-guided diagnosis of subepithelial tumors. Gastroenterol Clin N Am. 2012;41(1):47–63.
5. Cho JW, Korean ESDSG. Current guidelines in the management of upper gastrointestinal subepithelial tumors. Clin Endosc. 2016;49:235–40.
6. Group EESNW. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):i21–6.
7. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:S36–63.
8. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1-41 (quiz 542–544).
9. Zhu L, Khan S, Misra A, et al. Management of small gastric gastrointestinal stromal tumors: a prospective study. Cancer. 2019;54:297–302.
10. Ko EJ, Cho JW, Kwak KS, et al. Endoscopic enucleation is effective and relatively safe in small gastric subepithelial tumors originating from muscularis propria. Dig Dis Sci. 2019;64:524–31.
11. Pang T, Zhao Y, Fan T, et al. Comparison of safety and outcomes between endoscopic and surgical resections of small (≤ 5 cm) primary gastric gastrointestinal stromal tumors. J Cancer. 2018;10:4132–41.
12. Marcella C, Sarwar S, Ye H, et al. Efficacy and safety of endoscopic treatment for gastrointestinal stromal tumors in the upper gastrointestinal tract. Clin Endosc. 2020;53:458–65.
13. Feng F, Liu Z, Zhang X, et al. Comparison of endoscopic and open resection for small gastric gastrointestinal stromal tumor. Transl Oncol. 2015;8:504–8.
14. Yang F, Wang S, Sun S, et al. Factors associated with endoscopic full-thickness resection of gastric submucosal tumors. Surg Endosc. 2015;29:3588–93.
15. Hu J, Liu X, Ge N, et al. Role of endoscopic ultrasound and endoscopic resection for the treatment of gastric schwannoma. Medicine (Baltimore). 2017;96:e7175.
16. Ge N, Hu JL, Yang F, et al. Endoscopic full-thickness resection for treating small tumors originating from the muscularis propria in the gastric fundus: an improvement in technique over 15 years. World J Gastroenterol. 2019;11:1054–64.
17. Yang Z, Feng X, Zhang P, et al. Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review. Surg Endosc. 2019;33:2982–90.
18. Kindblom LG, Remotti HE, Aldenberg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–69.
19. Grignol VP, Termuhlen PM. Gastrointestinal stromal tumor surgery and adjuvant therapy. Surg Clin N Am. 2011;91:1079–87.
20. Valsangkar N, Sehdev A, Misra S, et al. Current management of gastrointestinal stromal tumors: surgery, current biomarkers, mutations, and therapy. Surg Today. 2015;158:1149–64.
21. Novai A, Bhakta H, Pais S, et al. Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol. 2005;20:818–24.
22. Committee ASoP, Gan S, Rajan E, et al. Role of EUS. Gastroenterol Endosc. 2007;66:425–34.
23. Palazzo L, Landi B, Cellier C, et al. Endosonographic features predictive of benign and malignant gastrointestinal submucosal cell tumors. Gut. 2000;46:88–92.
24. Onishi M, Tominaga K, Sugimoto S, et al. Internal hypoechoic feature by EUS as a possible predictive marker for the enlargement potential of gastric GI stromal tumors. Gastrointest Endosc. 2012;75:731–8.
25. Pesenti C, Bories E, Callolli F, et al. Characterization of subepithelial lesions of the stomach and esophagus by contrast-enhanced EUS: a retrospective study. Endosc Ultrasound. 2019;8:439–9.
26. Yamashita Y, Kato J, Ueda K, et al. Contrast-enhanced endoscopic ultrasonography can predict a higher malignant potential of gastrointestinal stromal tumors by visualizing large newly formed vessels. J Clin Ultrasound. 2015;43:89–97.
27. Gao Z, Wang C, Xu Q, et al. The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors. BMC Gastroenterol. 2017;17:1–8.
28. Okuwaki K, Masutani H, Kida M, et al. Diagnostic efficacy of white core cutoff lengths obtained by EUS-guided fine-needle biopsy using a novel 22G fransen biopsy needle and sample isolation processing by stereomicroscopy for subepithelial lesions. Endosc Ultrasound. 2020;9(3):187–92.
29. De Grazie M, Cinò SF, Gabbielli A, et al. Pancreatico-gastric fistula mimicking malignant infiltration following transgastric EUS-FNA of resectable pancreatic ductal adenocarcinoma. Endosc Ultrasound. 2020;9(2):138–40.
30. Kuwatan A, Sakamoto N. Evolution and a promising role of EUS-FNA in gene and future analyses. Endosc Ultrasound. 2020;9(3):151–3.
31. Kovacevic B, Vilmann P. EUS tissue acquisition: from A to B. Endosc Ultrasound. 2020;9(4):225–31.
32. Lee CK, Chung IK, Lee SH, et al. Endoscopic partial resection with the unroofing technique for reliable tissue diagnosis of upper GI subepithelial tumors originating from the muscularis propria on EUS (with video). Gastrointest Endosc. 2010;71:188–94.
33. Hoda KM, Rodriguez SA, Faigel DO. EUS-guided sampling of suspected GI stromal tumors. Gastrointest Endosc. 2009;69:1218–23.
34. El Chaﬁ A, Chen H, Yin Y, et al. Comparison of FNA and ﬁne-needle biopsy for EUS-guided sampling of suspected GI stromal tumors. Gastrointest Endosc. 2017;86:510–5.
35. Akahoshi K, Sumida Y, Matsu N, et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided ﬁne needle aspiration. World J Gastroenterol. 2007;13:2077–82.
36. Mekky MA, Yamao K, Sawaki A, et al. Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors. Gastrointest Endosc. 2010;71:913–9.
37. Rossi S, Gasparrone D, Toffolotti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34:1480–91.
38. Cai MY, Martin Carreras-Presas F, Zhou PH. Endoscopic full-thickness resection for gastrointestinal submucosal tumors. Dig Endosc. 2018;30(Suppl 1):17–24.
39. Shen C, Chen H, Yin Y, et al. Endoscopic versus open resection for small gastrointestinal stromal tumors: safety and outcomes. Medicine (Baltimore). 2015;94:e376.
40. Joo MK, Park JJ, Kim H, et al. Endoscopic versus surgical resection of GI stromal tumors in the upper GI tract. Gastrointest Endosc. 2016;83:318–26.
41. Feng Y, Yu L, Yang S, et al. Endolumenal endoscopic full-thickness resection of muscularis propria-originating gastric submucosal tumors. J Laparoendosc Adv Surg Tech A. 2014;24:171–6.
42. Kono M, Kanesaka T, Maekawa A, et al. Delayed perforation after gastric endoscopic submucosal dissection can be treated by using over-the-scope clips. Ann Gastroenterol. 2019;32:526.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.